ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma

Zhang, Minghui; Ma, Jianli; Guo, Qiuyue; Ding, Shuang; Wang, Yan; Pu, Haihong*哈尔滨医科大学
Frontiers in Immunology2022-2-22DOI: 10.3389/fimmu.2022.806877
12被引8阅读
引用收藏
分享

摘要

The presence of infiltrating CD8(+) T lymphocytes in the tumor microenvironment of lung adenocarcinoma (LUAD) is correlated with improved patient prognosis, but underlying regulatory mechanisms remain unknown. To identify biomarkers to improve early diagnosis and treatment of LUAD, we downloaded 13 immune cell line-associated datasets from the GEO database. We identified CD8(+) T cell-associated genes via weighted correlation network analysis. We constructed molecular subtypes based on CD8(+) T cell-associated genes and constructed a multi-gene signature. We identified 252 CD8(+) T cell-associated genes significantly enriched in immune function-related pathways and two molecular subtypes of LUAD (immune cluster 1 [IC1] and IC2) using our CD8(+) T cell-associated gene signature. Patients with the IC2 subtype had a higher tumor mutation burden and lower immune infiltration scores, whereas those with the IC1 subtype were more sensitive to immune checkpoint inhibitors. Prioritizing the top candidate genes to construct a 10-gene signature, we validated our model using independent GSE and TCGA datasets to confirm its robustness and stable prognostic ability. Our risk model demonstrated good predictive efficacy using the Imvigor210 immunotherapy dataset. Thus, we established a novel and robust CD8(+) T cell-associated gene signature, which could help assess prognostic risk and immunotherapy response in LUAD patients.

学科与关键词

关键词
lung adenocarcinomaCD8(+) T lymphocytesgene signatureprognosisimmunotherapy response
相关
加载中…
  • Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
    Li, Na; Wang, Jiahong; Zhan, Xianquan*Frontiers in Immunology, 2021, 12: 752643.被引 19
  • Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.
    Yi, Ming; Li, Anping; Zhou, Linghui; Chu, Qian; Luo, Suxia*; Wu, Kongming*Cancer Immunol Immunother, 2021, 70(6): 1705-1719.
  • Development and validation of an immune-related gene signature for prognosis in Lung adenocarcinoma
    Guo, Zehuai; Qi, Xiangjun; Li, Zeyun; Yang, Jianying; Sun, Zhe; Li, Peiqin; Chen, Ming; Cao, Yang*IET Systems Biology, 2023, 17(1): 27-38.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2022-02-22
卷期
第 13 卷
页码
806877
DOI
10.3389/fimmu.2022.806877
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Natural Science Foundation of Heilongjiang Province [LH2019H040]; China Postdoctoral Science Foundation [2018M640309]; Heilongjiang Province Postdoctoral Science Foundation [2018JTC]; Haiyan Foundation of Harbin Medical University Cancer Hospital [JJMS2021-14]

作者

  • Z

    Zhang, Minghui (第一作者)

    harbin med univ

  • M

    Ma, Jianli

    harbin med univ

查看全部 6 位作者收起作者
  • G

    Guo, Qiuyue

    harbin med univ

  • D

    Ding, Shuang

    harbin med univ

  • W

    Wang, Yan

    harbin med univ

  • P

    Pu, Haihong (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417